SEARCH

SEARCH BY CITATION

References

  • 1
    AIDS Epidemic update. UNAIDS/WHO. Geneva 2009. http://data.unaids.org/pub/report/2009/jc1700_epi_update_2009_en.pdf.
  • 2
    Dunn, D. T., Newell, M. L., Ades, A. E. and Peckham, C. S., Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992. 340: 585588.
  • 3
    Kuhn, L., Stein, Z. and Susser, M., Preventing mother-to-child HIV transmission in the new millennium: the challenge of breast feeding. Paediatr. Perinat. Epidemiol. 2004. 18: 1016.
  • 4
    Kuhn, L., Aldrovandi, G. M., Sinkala, M., Kankasa, C., Semrau, K., Mwiya, M., Kasonde, P. et al., Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N. Engl. J. Med. 2008. 359: 130141.
  • 5
    Mbori-Ngacha, D., Nduati, R., John, G., Reilly, M., Richardson, B., Mwatha, A., Ndinya-Achola, J. et al., Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: a randomizedclinical trial. J. Am. Med. Assoc. 2001. 286: 24132420.
  • 6
    Safrit, J. T., Ruprecht, R., Ferrantelli, F., Xu, W., Kitabwalla, M., Van Rompay, K., Marthas, M. et al., Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J. Acquir. Immune. Defic. Syndr. 2004. 35: 169177.
  • 7
    Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N. et al., Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009. 361: 22092220.
  • 8
    Hanke, T. and McMichael, A. J., Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat. Med. 2000. 6: 951955.
  • 9
    Hanke, T., Goonetilleke, N., McMichael, A. J. and Dorrell, L., Clinical experience with plasmid DNA- and modified vaccinia vaccine Ankara (MVA)-vectored HIV-1 clade A vaccine inducing T cells. J. Gen. Virol. 2007. 88: 112.
  • 10
    Bridgeman, A., Roshorm, Y., Lockett, L. J., Xu, Z.-Z., Hopkins, R., Shaw, J., Both, G. W. and Hanke, T., Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine 2009. 28: 474483.
  • 11
    Im, E. J., Saubi, N., Virgili, G., Sander, C., Teoh, D., Gatell, J. M., McShane, H. et al., Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. J. Virol. 2007. 81: 94089418.
  • 12
    Rosario, M., Fulkerson, J., Soneji, S., Parker, J., Im, E. J., Borthwick, N., Bridgeman, A. et al., Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques. J. Virol. 2010. 84: 78157821.
  • 13
    Rosario, M., Hopkins, R., Fulkerson, J., Borthwick, N., Quigley, M. F., Joseph, J., Douek, D. C. et al, Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques. J. Virol. 2010. 84: 58985908.
  • 14
    Hanke, T., On the growing complexity of HIV-1 vaccines. Future Gene Ther. 2010. 4: 543552.
  • 15
    Larke, N., Murphy, A., Wirblich, C., Teoh, D., Estcourt, M. J., McMichael, A. J., Roy, P. and Hanke, T., Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen. J. Virol. 2005. 79: 1482214833.
  • 16
    Im, E.-J., Hong, J. P., Roshorm, Y., Bridgeman, A., Létourneau, S., Liljeström, P., Potash, M. J. et al., Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog. 2011. 7: e1002041.
  • 17
    Honeyborne, I., Prendergast, A., Pereyra, F., Leslie, A., Crawford, H., Payne, R., Reddy, S. et al., Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J. Virol. 2007. 81: 36673672.
  • 18
    Kiepiela, P., Ngumbela, K., Thobakgale, C., Ramduth, D., Honeyborne, I., Moodley, E., Reddy, S. et al., CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 2007. 13: 4653.
  • 19
    Rolland, M., Heckerman, D., Deng, W., Rousseau, C. M., Coovadia, H., Bishop, K., Goulder, P. J. et al., Broad and Gag-Biased HIV-1 Epitope Repertoires Are Associated with Lower Viral Loads. PLoS One 2008. 3: e1424.
  • 20
    Fischer, W., Perkins, S., Theiler, J., Bhattacharya, T., Yusim, K., Funkhouser, R., Kuiken, C. et al., Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 2007. 13: 100106.
  • 21
    Letourneau, S., Im, E.-J., Mashishi, T., Brereton, C., Bridgeman, A., Yang, H., Dorrell, L. et al., Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2007. 2: e984.
  • 22
    Paris, R. M., Kim, J. H., Robb, M. L. and Michael, N. L., Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev. Vaccines 2010. 9: 10551069.
  • 23
    Barefoot, B., Thornburg, N. J., Barouch, D. H., Yu, J. S., Sample, C., Johnston, R. E., Liao, H. X. et al., Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine 2008. 26: 61086118.
  • 24
    Hanke, T., Blanchard, T. J., Schneider, J., Hannan, C. M., Becker, M., Gilbert, S. C., Hill, A. V. S. et al., Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998. 16: 439445.
  • 25
    Hill, A. V., Reyes-Sandoval, A., O'Hara, G., Ewer, K., Lawrie, A., Goodman, A., Nicosia, A. et al., Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccin. 2010. 6: 7883.
  • 26
    Chapman, R., Chege, G., Shephard, E., Stutz, H. and Williamson, A. L., Recombinant Mycobacterium bovis BCG as an HIV vaccine vector. Curr. HIV Res. 2010. 8: 282298.
  • 27
    Fennelly, G. J., Flynn, J. L., ter Meulen, V., Liebert, U. G. and Bloom, B. R., Recombinant bacille Calmette-Guerin priming against measles. J. Infect. Dis. 1995. 172: 698705.
  • 28
    Govan, V. A., Christensen, N. D., Berkower,C., Jacobs, W. R., Jr. and Williamson, A. L., Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. Vaccine 2006. 24: 20872093.
  • 29
    Grode, L., Seiler, P., Baumann, S., Hess, J., Brinkmann, V., Nasser Eddine, A., Mann, P. et al., Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J. Clin. Invest. 2005. 115: 24722479.
  • 30
    Langermann, S., Palaszynski, S. R., Burlein, J. E., Koenig, S., Hanson, M. S., Briles, D. E. and Stover, C. K., Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guerin vaccines expressing pneumococcal surface protein A. J. Exp. Med. 1994. 180: 22772286.
  • 31
    Matsumoto, S., Yukitake, H., Kanbara, H. and Yamada, T., Recombinant Mycobacterium bovis bacillus Calmette-Guerin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies. J. Exp. Med. 1998. 188: 845854.
  • 32
    Stover, C. K., Bansal, G. P., Hanson, M. S., Burlein, J. E., Palaszynski, S. R., Young, J. F., Koenig, S. et al., Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J. Exp. Med. 1993. 178: 197209.
  • 33
    Streit, J. A., Recker, T. J., Donelson, J. E. and Wilson, M. E., BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice. Exp. Parasitol. 2000. 94: 3341.
  • 34
    Edelman, R., Palmer, K., Russ, K. G., Secrest, H. P., Becker, J. A., Bodison, S. A., Perry, J. G. et al., Safety and immunogenicity of recombinant bacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer-surface protein A (OspA) liporpotein in adults volunteers: a candidate Lyme disease vaccine. Vaccine 1999. 17: 904919.
  • 35
    Calmette, A., La Vaccination Preventive Contre la Tuberculose. Masson, Paris 1927.
  • 36
    Fine, P. E. M., Carneiro, I. A. M., Milstien, J. B. and Clemens, C. J., Issues relating to the use of BCG in immunization programmes. A discussion document. WHO, Geneva 1999. http://www.who.int/vaccines-documents/docsPDF99/www9943.pdf.
  • 37
    Brosch, R., Gordon, S. V., Garnier, T., Eiglmeier, K., Frigui, W., Valenti, P., Dos Santos, S. et al., Genome plasticity of BCG and impact on vaccine efficacy. Proc. Natl. Acad. Sci. USA 2007. 104: 55965601.
  • 38
    Fine, P. E., Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995. 346: 13391345.
  • 39
    Trunz, B. B., Fine, P. and Dye, C., Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006. 367: 11731180.
  • 40
    Sun, R., Skeiky, Y. A. W., Izzo, A., Dheenadhayalan, V., Imam, Z., Penn, E., Stagliano, K. et al., Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009. 27: 44124423.
  • 41
    Pavelka M. S., Jr. and Jacobs, W. R., Jr., Comparison of the construction of unmarked deletion mutations in Mycobacterium smegmatis, Mycobacterium bovis bacillus Calmette-Guerin, and Mycobacterium tuberculosis H37Rv by allelic exchange. J. Bacteriol. 1999. 181: 47804789.
  • 42
    Andersson, G. E. and Sharp, P. M., Codon usage in the Mycobacterium tuberculosis complex. Microbiology 1996. 142: 915925.
  • 43
    Hopkins, R., Bridgeman, A., Joseph, J., Gilbert, S. C., McShane, H. and Hanke, T., Dual Neonate Vaccine Platform against HIV-1 and M. tuberculosis. PLoS One 2011. 6: e20067.
  • 44
    Saubi, N., Im, E. J., Fernandez-Lloris, R., Gil, O., Cardona, P. J., Gatell, J. M., Hanke, T. and Joseph, J., Newborn mice vaccination with BCG.HIVA + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes. Clin. Dev. Immunol. 2011. 2011: 516219.
  • 45
    Takahashi, H., Cohen, J., Hosmalin, A., Cease, K. B., Houghten, R., Cornette, J. L., DeLisi, C. et al., An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 1988. 85: 31053109.
  • 46
    Gill, D. K., Huang, Y., Levine, G. L., Sambor, A., Carter, D. K., Sato, A., Kopycinski, J. et al., Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One 2010. 5: e14330.
  • 47
    Kaltsidis, H., Cheeseman, H., Kopycinski, J., Ashraf, A., Cox, M. C., Clark, L., Anjarwalla, I. et al., Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trials. J. Immunol. Methods 2011. DOI: 10.1016/j.jim.2011.05.007.
  • 48
    Soares, A. P., Scriba, T. J., Joseph, S., Harbacheuski, R., Murray, R. A., Gelderbloem, S. J., Hawkridge, A. et al., Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J. Immunol. 2008. 180: 35693577.
  • 49
    Appay, V., Dunbar, P. R., Callan, M., Klenerman, P., Gillespie, G. M., Papagno, L., Ogg, G. S. et al., Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 2002. 8: 379385.
  • 50
    Tatsis, N., Fitzgerald, J. C., Reyes-Sandoval, A., Harris-McCoy, K. C., Hensley, S. E., Zhou, D., Lin, S. W. et al., Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 2007. 110: 19161923.
  • 51
    Horwitz, M. and Harth, G., A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. 2003. 71: 1672.
  • 52
    Lagranderie, M. R., Balazuc, A. M., Deriaud, E., Leclerc, C. D. and Gheorghiu, M., Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect. Immun. 1996. 64: 19.
  • 53
    Wu, B., Huang, C., Garcia, L., Ponce de Leon, A., Osornio, J. S., Bobadilla-del-Valle, M., Ferreira, L. et al., Unique gene expression profiles in infants vaccinated with different strains of Mycobacterium bovis bacille Calmette-Guerin. Infect. Immun. 2007. 75: 36583664.
  • 54
    Al-Zarouni, M. and Dale, J. W., Expression of foreign genes in Mycobacterium bovis BCG strains using different promoters reveals instability of the hsp60 promoter for expression of foreign genes in Mycobacterium bovis BCG strains. Tuberculosis (Edinb) 2002. 82: 283291.
  • 55
    Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M. and Berger, E. A., CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996. 272: 19551958.
  • 56
    Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C. and Lusso, P., Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995. 270: 18111815.
  • 57
    Poli, G., Bressler, P., Kinter, A., Duh, E., Timmer, W. C., Rabson, A., Justement, J. S. et al., Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J. Exp. Med. 1990. 172: 151158.
  • 58
    Katsikis, P. D., Mueller, Y. M. and Villinger, F., The cytokine network of acute HIV infection: A promising target for vaccines and therapy to reduce viral set-point? PLoS Pathog. 2011. 7: e1002055.
  • 59
    Both, G. W., Cameron, F., Collins, A., Lockett, L. J. and Shaw, J., Production and release testing of ovine atadenovirus vectors. Methods Mol. Med. 2007. 130: 6990.